MedTrace Logo

The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma

NCT04489264 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2020-12-04

No results posted yet for this study

Summary

The role of autologous stem cell transplantation (ASCT) in the first remission (CR1 \& PR1) of peripheral T-cell lymphomas (PTCLs) is not well defined. This study analyzed the impact of ASCT on the clinical outcomes of patients with newly diagnosed PTCL in CR1 and PR1.

Conditions

  • Peripheral T Cell Lymphoma

Interventions

DRUG

Transplant, Autologous

high dose chemotherapy followed by autologous stem cell transplantation

Sponsors & Collaborators

  • Peking University

    lead OTHER

Principal Investigators

  • Jun Zhu, Dr. · Peking University Cancer Hospital & Institute

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-30
Primary Completion
2023-11-30
Completion
2025-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04489264 on ClinicalTrials.gov